PTGX Stock Overview
A biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 4/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Protagonist Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$40.24 |
52 Week High | US$42.67 |
52 Week Low | US$13.72 |
Beta | 2.12 |
11 Month Change | 9.50% |
3 Month Change | 25.99% |
1 Year Change | 117.04% |
33 Year Change | -13.76% |
5 Year Change | 239.58% |
Change since IPO | 243.93% |
Recent News & Updates
Recent updates
Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't
Apr 13Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise
Feb 25We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth
Dec 28We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth
Jul 04Newsflash: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Have Been Trimming Their Revenue Forecasts
Mar 20An Intrinsic Calculation For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Suggests It's 42% Undervalued
Feb 06We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate
Jun 15Protagonist: Too Many Red Flags
Jun 08Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%
May 11Protagonist Is Still Being Undervalued Like There's Real Risk
Feb 01Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth
Jan 04Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Just Slashed This Year's Estimates
Aug 06Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Are Reducing Their Forecasts For This Year
Jun 19Protagonist Therapeutics closes $132M capital raise
Jun 18Protagonist wins FDA Breakthrough Therapy Designation for blood cancer therapy
Jun 03This Is Why Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Can Expect A Bump Up In Their Pay Packet
May 21Protagonist EPS beats by $0.03, beats on revenue
May 04Shareholder Returns
PTGX | US Biotechs | US Market | |
---|---|---|---|
7D | 12.4% | 3.8% | 4.5% |
1Y | 117.0% | 12.6% | 21.7% |
Return vs Industry: PTGX exceeded the US Biotechs industry which returned 11.8% over the past year.
Return vs Market: PTGX exceeded the US Market which returned 20.3% over the past year.
Price Volatility
PTGX volatility | |
---|---|
PTGX Average Weekly Movement | 8.3% |
Biotechs Industry Average Movement | 10.6% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 14.9% |
10% least volatile stocks in US Market | 3.2% |
Stable Share Price: PTGX's share price has been volatile over the past 3 months.
Volatility Over Time: PTGX's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 125 | Dinesh Patel | www.protagonist-inc.com |
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113.
Protagonist Therapeutics, Inc. Fundamentals Summary
PTGX fundamental statistics | |
---|---|
Market cap | US$2.37b |
Earnings (TTM) | US$169.95m |
Revenue (TTM) | US$319.12m |
13.9x
P/E Ratio7.4x
P/S RatioIs PTGX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PTGX income statement (TTM) | |
---|---|
Revenue | US$319.12m |
Cost of Revenue | US$0 |
Gross Profit | US$319.12m |
Other Expenses | US$149.17m |
Earnings | US$169.95m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 2.89 |
Gross Margin | 100.00% |
Net Profit Margin | 53.26% |
Debt/Equity Ratio | 0% |
How did PTGX perform over the long term?
See historical performance and comparison